SEC Form 4 · accession 0001479290-18-000013
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lauren P Silvernail
Officer — CFO, CBO & Secretary
Period of report
Jan 28, 2018
Accepted (ET)
Jan 30, 2018 · 9:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 28, 2018 | F | 990 | $33.50 | D | 65,965 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares withheld by and surrendered to the issuer on January 28, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2015 Restricted Stock Award ("RSA") for 7,290 shares. The RSA vests in three (3) equal annual installments from January 28, 2015, subject to Mrs. Silvernail's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan) on each vesting date.
- F2The fair market value was determined on January 26, 2018 per the Company Policy, as this was the last trading day before the vest date.